title: [Dipeptidyl-peptidase-4 inhibitors (gliptins): a new class of oral antidiabetic drugs].
abstract: Nearly 90% of the diabetic patients are suffering of type 2 diabetes while approximately 60-65% of patients with type 2 diabetes are treated with oral antidiabetic drugs. In the last couple of years a new treatment option, namely incretin-based therapy, became available. The dipeptidyl-peptidase-4-inhibitors (gliptins) are designated as incretin enhancers. Using gliptins, sustained glycemic control can be achieved without gaining weight and increasing the risk of hypoglycemia. All gliptins (sitagliptin, vildagliptin, saxagliptin, linagliptin) can be used as tablets without a need for dose titration. For treating patients with type 2 diabetes, gliptins can primarily be used in combination with metformin.
authors: Bajcsy-Zsilinszky Kórház III. Belgyógyászati Osztály Budapest Maglódi út 89-91. 1106. gyjermendy@mail.datanet.hu
authors: György
authors: G
authors: Jermendy
mesh_terms: D000218:Adamantane / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000378:metabolism; D004151:Dipeptides / Q000494:pharmacology / Q000627:therapeutic use; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D006801:Humans; D007004:Hypoglycemic Agents / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use*; D054795:Incretins / Q000378:metabolism; D000069476:Linagliptin; D008687:Metformin / Q000008:administration & dosage / Q000494:pharmacology; D009570:Nitriles / Q000494:pharmacology / Q000627:therapeutic use; D011687:Purines / Q000494:pharmacology / Q000627:therapeutic use; D011719:Pyrazines / Q000494:pharmacology / Q000627:therapeutic use; D011759:Pyrrolidines / Q000494:pharmacology / Q000627:therapeutic use; D011799:Quinazolines / Q000494:pharmacology / Q000627:therapeutic use; D000068900:Sitagliptin Phosphate; D013607:Tablets; D016896:Treatment Outcome; D014230:Triazoles / Q000494:pharmacology / Q000627:therapeutic use; D000077597:Vildagliptin
chemical_list: D004151:Dipeptides; D054873:Dipeptidyl-Peptidase IV Inhibitors; D007004:Hypoglycemic Agents; D054795:Incretins; D009570:Nitriles; D011687:Purines; D011719:Pyrazines; D011759:Pyrrolidines; D011799:Quinazolines; D013607:Tablets; D014230:Triazoles; D000069476:Linagliptin; D008687:Metformin; C502994:saxagliptin; D000077597:Vildagliptin; D000218:Adamantane; D000068900:Sitagliptin Phosphate